Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

By Natalie Morrison

- Last updated on GMT

Related tags: European union, Vp, Executive director

The proposed changes to European clinical trial regulations accepted by the European Commission (EC) in July will put Europe on an equal playing field, according to Clinipace’s Andrea Schiefer.

Speaking to Outsourcing-Pharma.com, the firm's VP of European clinical operations and executive director of pharmacovigilance said the directive will correct the mistakes of the past that have caused a reduction of clinical trials in Europe.

When asked if it is ethical to make one market very attractive for conducting trials, she said: “I don’t think it will lead to a great influx in trials. It will be a slow development and it will make it more proportionate and more fair compared to the situation now.”

Schiefer added that if anything, the EC could have implemented more scientific expert committees looking at certain indications when forming the new guidelines.

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars